Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Positive results from FractalDx study published

June 7, 2019
Download  full announcement Demonstrates ability to predict early rejection in kidney transplant Supports successful development of a predictive blood test for transplant patients Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease,

FDA grants Breakthrough Device designation to KidneyIntelX™

May 2, 2019
Download  full announcement Provides priority regulatory review of  AI-enabled diagnostic for fast-progressing kidney disease Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that it has been granted Breakthrough Device

FDA Grants Breakthrough Device Designation to KidneyIntelX™

May 2, 2019
Provides Priority Regulatory Review of AI-Enabled Diagnostic for Fast-Progressing Kidney Disease NEW YORK, May 2, 2019 /PRNewswire/ --  Renalytix AI plc  (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that it has been granted
Displaying 541 - 550 of 582